Hg

Hg describes itself as leading private equity in AI transformation, building businesses that redefine how people work. It states that over 25 years, through successive waves of technology change, it has become a leading expert in investing in and supporting businesses transforming workplace automation and professional productivity. Its portfolio comprises 60+ companies, with GenAI deployment across 1600+ live projects, an approximate $260m budgeted EBITDA impact from AI initiatives, and 100+ agentic products and features launched. Its value creation team of 100+ AI experts embeds directly into portfolio companies, and through Hg Catalyst, its AI incubator, it builds and ships agentic AI products. It also connects 2,750+ senior executives through HIVE.

Hg states that over 25 years, through successive waves of technology change, it has become a leading expert in investing in and supporting businesses transforming workplace automation and professional productivity. It describes itself as leading private equity in AI transformation, building businesses that redefine how people work. Its portfolio of 60+ companies is presented as one of the largest software ecosystems deploying AI at scale, with GenAI deployment across 1600+ live projects, an approximate $260m budgeted EBITDA impact from AI initiatives, and 100+ agentic products and features launched. Its value creation team of 100+ AI experts operates with startup intensity, embedding directly into portfolio companies, and through Hg Catalyst, its AI incubator, it builds and ships agentic AI products at speed. It connects 2,750+ senior executives through HIVE.

Leading private equity in AI transformation.

• 2021

  CMA fines Advanz over thyroid tablet pricing

  The UK Competition and Markets Authority imposed fines of more than £100 million on Advanz and its former private equity owners after finding that Advanz charged excessive and unfair prices for liothyronine tablets.

  Source

Read more

• 2021.07.29

  Reported2021.07.29

  CMA fines Advanz over thyroid tablet pricing[2]CMA fines Advanz over thyroid tablet pricingtheguardian.com

  The UK Competition and Markets Authority imposed fines of more than £100 million on Advanz and its former private equity owners after finding that Advanz charged excessive and unfair prices for liothyronine tablets.

Read more

1. 1Navigate the future | Hghgcapital.com
2. 2CMA fines Advanz over thyroid tablet pricingtheguardian.com